HYBRID EVENT
This 3-day hybrid event will cover the latest progressions in solid tumor CAR-T therapies, how to make CAR-T therapies safer, and the development of off-shelf CAR-T T-cells.
This 3-day hybrid event will cover the latest progressions in solid tumor CAR-T therapies, how to make CAR-T therapies safer, and the development of off-shelf CAR-T T-cells.
By signing up, you’re agreeing to receive email from SCB. But rest assured: we respect your privacy.